Uncategorized
-
Nubeva’s Breadcrumbs
Frontier AI, Patents and the UK Trail Last year I wrote Decrypting The Exit: Nubeva’s Patent Play. The thesis was fairly straightforward: Nubeva Technologies was beginning to look like a company methodically assembling a potentially valuable software and intellectual-property asset focused on ransomware reversal. Building a strategic technology asset is difficult. You need novel, genuinely… Continue reading
-
A Monster In The Deep
I’m in deep. As an investor in Reviva Pharmaceuticals (OTC: RVPH), I follow the company and its scientific progress very closely. So imagine my surprise when my research on Reviva’s patents stirred up something I consider very important — something that, as far as I can tell, hasn’t yet been meaningfully discussed or analyzed. There is a… Continue reading
-
Reviva’s Negative (Symptom) Potential
Followers of my blog – Or investors in Reviva Pharmaceuticals (OTC:RVPH) know that the journey of Reviva Pharmaceuticals (OTC: RVPH) has been both positive and negative. Positive, in the sense that the company has spent more than a decade advancing its drug brilaroxazine through multiple stages of scientific and clinical success, bringing the program to the threshold… Continue reading
-
MapLight Therapeutics: A Small Probability Upgrade Before the Real Test(s)
Earlier this year, I wrote about MapLight Therapeutics (NASDAQ: MPLT) as a case study in probability engineering. That post can be found here: https://dtm5.com/2026/02/12/maplight-therapeutics-engineering-probability-in-cns-drug-development/ CNS drug development has a long and colorful history of humbling investors. My original post was about MapLight appearing to have several attributes that could justify assigning probabilities above ordinary Phase 2… Continue reading
-
RVPH: A New Day for Brilaroxazine
Followers of my blog know that I’ve been an investor in (and out) of RVPH’s shares and warrants for approximately 5 years. It has been a heck of a ride, fraught with successes (P2! P3! OLE!), Financial Struggles (Predatory Financings!), soft market comms (Dr Bhat = Amazing Scientist, not a compelling public speaker!), and of… Continue reading
-
From Scale to Sale
I’ve been following Rivalry Corp (RVLY: TSX) for the past couple years. Back in January, I blogged about Rivalry and their re-org / recap, and hypothesized about what outcomes could look like if things ‘turned around’. Well, colour me surprised. What looked like a re-org to scale, was actually a re-org for sale. What initially… Continue reading
-
Northstar Gaming & Playtech PLC: A Stew of Debt, Strategy, Risk and Opportunity
Note: This post is an updated version of my August 25, 2025 post entitled “Unlocking IRR: Playtech’s Strategic Impact on NorthStar Gaming“, taking into account recent developments. When businesses make investments in other businesses, a key metric they consider is Internal Rate of Return (IRR). In simple terms, the IRR represents the expected compounded annual return… Continue reading
-
Who Should Own the Final Mile in CNS Drug Development? A Case Study in RVPH
This post is not about whether RVPH’s timeline is misunderstood. That question has largely been addressed in my previous post . Instead, this is about how late-stage schizophrenia assets are evaluated once the remaining risk is no longer scientific, but operational — and why that stage often forces a change in who carries the asset… Continue reading
-
Nubeva: Pioneering Ransomware Decryption Solutions
Nubeva Technologies is an early-stage cybersecurity company based in San Jose, California. Nubeva is developing a novel, breakthrough end-point ransomware decryption solution that enables the interception and complete reversal of ransomware infections. The benefit and economics of Nubeva’s solution are compelling. Their software is an inexpensive, lightweight and scalable endpoint technology. By quickly intercepting,… Continue reading
-
Scouting Nubeva
Nubeva is a silicon valley based company, which is listed on the TSX Venture Exchange with the symbol NBVA. Nubeva has developed a novel, groundbreaking solution to dealing with ransomware, a massive global plague. Their technology – an endpoint software that detects and captures ransomware keys, enables fast, immediate and complete reversal of a ransomware… Continue reading
-
The Dead Man’s Hand
On August 2, 1876, James Butler Hickok, known as ‘Wild Bill Hickok’ was playing poker at Nuttal & Mann’s Saloon No. 10 in Deadwood, Dakota. Poker was a passion of Wild Bill’s. And a profession. When playing, Bill would always sit with his back to the wall, so as to be able to see who was… Continue reading
-
Another Credibility Milestone for NBVA Achieved
DTM5 blogpost newsflash! I don’t usually post about news updates, but one of my key holdings, Nubeva Technologies, keeps on delivering. Here is today’s press release in it’s entirety. Full disclosure – I hold a meaningful long position in Nubeva. I’m very pleased with the company’s progress. I think this is important news, especially in… Continue reading
-
Options on Cingulate Inc.
Cingulate is an early stage Pharma company that is commercializing a drug candidate, CTx-1301. CTx-1301 is the long established and effective drug Dexmethylphenidate, used in the treatment of attention deficit hyper activity disorder (ADHD). Cingulate has packaged dexmethylphenidate in a patented, novel pill delivery platform which controls “drug release at precise, pre-defined times with no… Continue reading
-
Proof of Concept Achieved
Its the three year anniversary of the inception of the DTM5 Strategy! The first deposit was made on May 15, 2020. I launched my blog – The DTM5 Venture Investing Strategy – later that year to journal about my progress and process. The DTM5 strategy was conceived as a way to take advantage of the… Continue reading
-
How Time Flies – Almost 3 Years in Review
My original intent in the strategy was to focus on a select group of investments (5) and build good size positions in them and hold them until my thesis on each played out. Things shaped up a little differently. Continue reading
-
Thoughts on Nubeva Technologies
Nubeva Technologies (TSXV – NBVA) has the potential to be a great company. Its success will be based on the commercialization of it’s technology – A patented, novel software that intercepts and reverses ransomeware. Continue reading
-
DTM5 Holdings Update and Commentary
The summer is almost gone, and it has been a heck of a year so far. Most of my holdings have been beaten down along with everything else. I’ve made some serious adjustments since the start of the year. As I commented on my ‘Results & Asset Allocation’ page as of Dec 31, 2021, for… Continue reading
-
Mind the (Copper) Gap
When you ride the tube in London, you’ll be reminded to ‘Mind the Gap’. It is a warning to avoid getting stuck, or falling into the gap between the train and the platform which would result in tragedy. Well, this blog post is about Copper prices, and I’d like to remind you to ‘Mind the… Continue reading
-
Mid Week Musings
I’ve been deep into studying the economic environment. Inflation, war, Increasing interest rates, fiscal tightening, commodity madness, energy price shocks and real estate bubbles…..what a time to be an investor! Podcasts, blogs, interviews, conferences…..I’m deep down the rabbit hole. It is pretty clear that we are at a major economic and market inflection point (Duh!).… Continue reading
-
Improving Outcomes With Reviva Pharmaceuticals
I’ve been scouting for prospects. While doing research on a different pharmaceutical company, I discovered Reviva Pharmaceuticals (RVPH: NASDAQ). From the Reviva website: Reviva is a biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their families.” Of particular interest… Continue reading
-
Screening for Prospects
Every month or so I go on what I call a ‘scouting mission’. I spend an afternoon running stock filters, reading through Sedar documents, perusing company websites, and researching company management using tools such as Google, linkedin, Sedi, etc. This past Sunday I was rooting around an old favorite stock screener available on the Globe… Continue reading
-
‘Change is Inevitable. Growth is Optional’
What a week. What a couple years! In my 27 year professional career I’ve never seen this kind of environment – A time when it actually feels like things are massively changing. When it won’t necessarily be ‘business as usual’ over the next 5 and 10 years. Where the concepts and strategies that worked reliably… Continue reading
-
Update on Real Luck Group
The DTM5 Strategy makes investments in early stage ventures in sectors such as Technology, Decentralized Finance, and Metals. I follow a process when making investment, that looks like this: I attempt to determine the Merit of a company by running a series of fundemental screens, as well as a subjective evaluation of management competence and… Continue reading
-
Do Something Else
Some worship at the invent alter of Warren Buffet. Some at Benjamin Graham’s. Some Consider Jim Rogers or Ray Dalio their investing mentors. And certainly they can offer much wisdom and knowledge. But what if we look beyond professional investors, to ideas, hobbies, philosophies and strategies that are about something other than investing? What can… Continue reading